• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

    11/10/22 4:35:52 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    SC 13G/A 1 tm2229639d1_sc13ga.htm SC 13G/A

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    Otonomy, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    68906L105

     

    (CUSIP Number)

     

    October 31, 2022

     
     

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.  68906L105

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors LP

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    3,448,263

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    3,448,263

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,263

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.1% (1)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    IA, PN

     

     

    (1)Based on 56,990,363 shares of Common Stock (“Common Stock”) of Otonomy, Inc. (the “Issuer”) outstanding as of July 19, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on July 25, 2022.

     

     

     

     

    CUSIP No.  68906L105

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Baker Bros. Advisors (GP) LLC

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    3,448,263

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    3,448,263

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,263

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.1% (1)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    HC, OO

     

     

    (1)Based on 56,990,363 shares of Common Stock of the Issuer outstanding as of July 19, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on July 25, 2022.

     

     

     

     

    CUSIP No.  68906L105

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Felix J. Baker

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    3,448,263

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    3,448,263

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,263

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.1% (1)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    IN, HC

     

     

    (1)Based on 56,990,363 shares of Common Stock of the Issuer outstanding as of July 19, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on July 25, 2022.

     

     

     

     

    CUSIP No.  68906L105

     

     

    1

     

     

    NAMES OF REPORTING PERSONS

    Julian C. Baker

     

     

    2

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

     

    (a) ¨

    (b) ¨

     

     

    3

     

     

    SEC USE ONLY

     

     

    4

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

     

    5

     

     

    SOLE VOTING POWER

    3,448,263

     

     

    6

     

     

    SHARED VOTING POWER

    -0-

     

     

    7

     

     

    SOLE DISPOSITIVE POWER

    3,448,263

     

     

    8

     

     

    SHARED DISPOSITIVE POWER

    -0-

     

     

    9

     

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,263

     

     

    10

     

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

     

    ¨

     

    11

     

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.1% (1)

     

     

    12

     

     

    TYPE OF REPORTING PERSON (See Instructions)
    IN, HC

     

     

    (1)Based on 56,990,363 shares of Common Stock of the Issuer outstanding as of July 19, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on July 25, 2022.

     

     

     

     

    Amendment No. 2 to Schedule 13G

     

    This Amendment No. 2 to Schedule 13G amends and restates the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a)Name of Issuer:

     

    Otonomy, Inc. (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    4796 Executive Drive

     

    San Diego, California 92121

     

    Item 2(a)Name of Person Filing:

     

    This Amendment No. 2 is being filed jointly by the Reporting Persons.

     

    Item 2(b)Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c)Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”).

     

    Item 2(e)CUSIP Number:

     

    68906L105

     

     

     

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

      (a)  ¨ Broker or dealer registered under Section 15 of the Exchange Act.
       
      (b)  ¨ Bank as defined in section 3(a)(6) of the Exchange Act.
       
      (c)  ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.
       
      (d)  ¨ Investment company registered under section 8 of the Investment Company Act of 1940.
       
      (e)  x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
       
      (f)  ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
       
      (g)  x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
       
      (h)  ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
      (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
       
      (j)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4.Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 2 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as Common Stock that may be acquired upon exercise of pre-funded warrants with no expiration date with an exercise price of $0.001 per share of Common Stock (“Pre-Funded Warrants”), subject to the limitations on exercise described below.

     

    The information set forth below is based on 56,990,363 shares of Common Stock outstanding as of July 19, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on July 25, 2022. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

     

     

     

     

    Holder  Number of
    Shares of
    Common
    Stock we own or
    have the right
    to acquire within
    60 days
       Percent of Class
    Outstanding
     
    667, L.P.   272,747    0.5%
    Baker Brothers Life Sciences, L.P.   3,175,516    5.6%
    Total   3,448,263    6.1%

     

    The Pre-Funded Warrants are only exercisable to the extent that after giving effect or immediately prior to such exercise the holders thereof, their affiliates and any person who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 4.99% of the outstanding Common Stock (“Maximum Percentage”). By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. As a result of this restriction, the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the above holders may change depending upon changes in the outstanding Common Stock.

     

    Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨. N/A

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

     

     

     

    Item 8Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9Notice of Dissolution of Group:

     

    N/A

     

    Item 10Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    November 10, 2022

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      /s/ Julian C. Baker
      Julian C. Baker
     
      /s/ Felix J. Baker
      Felix J. Baker

     

     

     

    Get the next $OTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Otonomy Announces Change in Stock Exchange Listing

      SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan

      12/22/22 7:53:14 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Provides Corporate Update

      SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The

      12/19/22 4:53:38 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th

      11/10/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/14/23 4:06:58 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/13/23 8:49:22 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/10/23 4:29:37 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Otonomy Appoints Jill Broadfoot to Board of Directors

      SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P

      8/19/21 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Financials

    Live finance-specific insights

    See more
    • Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop

      7/25/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

      SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.  A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu

      7/18/22 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor

      5/9/22 4:04:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - OTONOMY, INC. (0001493566) (Issuer)

      2/24/23 4:53:45 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:31:39 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:30:19 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on Otonomy with a new price target

      HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      3/1/21 8:38:28 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Otonomy with a new price target

      HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      2/23/21 6:53:19 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Otonomy with a new price target

      Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously

      2/22/21 3:01:01 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Otonomy Inc.

      15-12G - OTONOMY, INC. (0001493566) (Filer)

      4/4/23 3:40:49 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:10 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:09 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care